Palisade Bio (PALI)
(Delayed Data from NSDQ)
$3.67 USD
+0.02 (0.55%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $3.66 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Income Statements
Fiscal Year end for Palisade Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 13 | 16 | 42 | 11 | 9 |
Income After Depreciation & Amortization | -13 | -16 | -42 | -11 | -9 |
Non-Operating Income | 1 | 1 | 18 | -6 | 0 |
Interest Expense | 0 | 0 | 2 | 0 | 0 |
Pretax Income | -12 | -14 | -27 | -16 | -8 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -12 | -14 | -27 | -16 | -8 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -12 | -14 | -27 | -16 | -8 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -13 | -16 | -42 | -11 | -8 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -13 | -16 | -42 | -11 | -9 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 0.46 | 0.06 | 0.01 | 0.00 | 0.00 |
Diluted EPS Before Non-Recurring Items | -26.99 | -247.83 | -3,245.88 | -5,261.32 | NA |
Diluted Net EPS (GAAP) | -26.99 | -247.83 | -2,541.23 | -5,261.32 | NA |
Fiscal Year end for Palisade Bio, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.67 | 3.29 | 3.77 | 3.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.67 | -3.29 | -3.77 | -3.61 |
Non-Operating Income | NA | 0.15 | 0.19 | 0.19 | 0.22 |
Interest Expense | NA | 0.00 | 0.00 | 0.01 | 0.00 |
Pretax Income | NA | -3.53 | -2.97 | -3.60 | -3.39 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.53 | -2.97 | -3.60 | -3.39 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.53 | -2.97 | -3.60 | -3.39 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 0.77 | 0.46 | 0.49 | 0.43 |
Diluted EPS Before Non-Recurring Items | NA | -4.59 | -3.75 | -7.35 | -7.95 |
Diluted Net EPS (GAAP) | NA | -4.59 | -3.60 | -7.35 | -7.95 |